A Phase I, Open-Label, Parallel-Group Study to Evaluate the Pharmacokinetics and Safety of Dolutegravir in Subjects With Renal Impairment and Healthy Matched Control Subjects (ING113125).
Latest Information Update: 31 Oct 2023
Price :
$35 *
At a glance
- Drugs Dolutegravir (Primary)
- Indications HIV-1 infections
- Focus Pharmacokinetics
- Sponsors ViiV Healthcare
- 13 Sep 2013 Results presented at the 53rd Interscience Conference on Antimicrobial Agents and Chemotherapy.
- 27 Apr 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 16 Mar 2012 Planned end date changed from 1 Oct 2011 to 1 Apr 2012 as reported by ClinicalTrials.gov.